Literature DB >> 11058896

PMM2 mutation spectrum, including 10 novel mutations, in a large CDG type 1A family material with a focus on Scandinavian families.

C Bjursell1, A Erlandson, M Nordling, S Nilsson, J Wahlström, H Stibler, B Kristiansson, T Martinsson.   

Abstract

Carbohydrate-deficient glycoprotein syndrome type IA (CDG IA) is an autosomal recessive disease characterized clinically by severe involvement of the central and peripheral nervous system, and biochemically by complex defects in carbohydrate residues in a number of serum glycoproteins. CDG IA is caused by mutations in the PMM2 gene located in chromosome region 16p13. In this study, 61 CDG type IA patients (122 chromosomes) were screened for mutations in the PMM2 gene using a combination of SSCP and sequence analysis. More than 95% of the mutations could be detected. All of them were missense mutations. Mutations 422G>A and 357C>A were strikingly more common in the material and comprised 58% of mutations detected. Of the 20 mutations found, 10 were not reported previously. Seven mutations, e.g. 26G>A (five alleles) and 548T>C (seven alleles), were found only in Scandinavian families. The most common genotype was 357C>A/422G>A (36%). Three patients were homozygous, 357C>A/357C>A (two cases), and 548T>C/548T>C (one case). No patients homozygous for the most common mutation 422G>A were detected. The different mutations were clustered e.g., in that most were located in exon 5 (five) and exon 8 (six), while no mutation was detected in exon 2. When the frequencies of each mutation were included, exon 5 comprised 61% (65 chromosomes) of the mutations; in Scandinavian patients the frequency of these mutations was 72%. Thus, analysis of exon five in these patients enables both reliable and time-saving first screening in prenatal diagnostic cases. This could be followed by a second step of additional strategies for the detection of other mutations. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11058896     DOI: 10.1002/1098-1004(200011)16:5<395::AID-HUMU3>3.0.CO;2-T

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  9 in total

1.  A nationwide survey of PMM2-CDG in Italy: high frequency of a mild neurological variant associated with the L32R mutation.

Authors:  Rita Barone; M Carrozzi; R Parini; R Battini; D Martinelli; M Elia; M Spada; F Lilliu; G Ciana; A Burlina; V Leuzzi; M Leoni; L Sturiale; G Matthijs; J Jaeken; M Di Rocco; D Garozzo; A Fiumara
Journal:  J Neurol       Date:  2014-10-30       Impact factor: 4.849

2.  High residual activity of PMM2 in patients' fibroblasts: possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency).

Authors:  S Grünewald; E Schollen; E Van Schaftingen; J Jaeken; G Matthijs
Journal:  Am J Hum Genet       Date:  2001-01-11       Impact factor: 11.025

3.  The molecular landscape of phosphomannose mutase deficiency in iberian peninsula: identification of 15 population-specific mutations.

Authors:  B Pérez; P Briones; D Quelhas; R Artuch; A I Vega; E Quintana; L Gort; M J Ecay; G Matthijs; M Ugarte; C Pérez-Cerdá
Journal:  JIMD Rep       Date:  2011-06-22

4.  Genetic predisposition to fetal alcohol syndrome: association with congenital disorders of N-glycosylation.

Authors:  María E de la Morena-Barrio; María J Ballesta-Martínez; Raquel López-Gálvez; Ana I Antón; Vanessa López-González; Laia Martínez-Ribot; José Padilla; Antonia Miñano; Oscar García-Algar; Miguel Del Campo; Javier Corral; Encarna Guillén-Navarro; Vicente Vicente
Journal:  Pediatr Res       Date:  2017-09-20       Impact factor: 3.756

5.  The Prevalence of PMM2-CDG in Estonia Based on Population Carrier Frequencies and Diagnosed Patients.

Authors:  Mari-Anne Vals; Sander Pajusalu; Mart Kals; Reedik Mägi; Katrin Õunap
Journal:  JIMD Rep       Date:  2017-07-07

6.  Employment of single-strand conformation polymorphism analysis in screening for α-1,3 glucosyltransferase gene mutation A333V in Croatian population.

Authors:  Sandra Supraha Goreta; Sanja Dabelic; Jerka Dumic
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

7.  Unusual presentation of congenital disorder of glycosylation type 1a: congenital persistent thrombocytopenia, hypertrophic cardiomyopathy and hydrops-like aspect due to marked peripheral oedema.

Authors:  Vera Noelle; Matthias Knuepfer; Ferdinand Pulzer; Volker Schuster; Werner Siekmeyer; Gert Matthijs; Christoph Vogtmann
Journal:  Eur J Pediatr       Date:  2005-01-12       Impact factor: 3.183

8.  Congenital disorder of glycosylation type Ia: heterogeneity in the clinical presentation from multivisceral failure to hyperinsulinaemic hypoglycaemia as leading symptoms in three infants with phosphomannomutase deficiency.

Authors:  B Shanti; M Silink; K Bhattacharya; N J Howard; K Carpenter; M Fietz; P Clayton; J Christodoulou
Journal:  J Inherit Metab Dis       Date:  2009-04-27       Impact factor: 4.982

Review 9.  Insights into complexity of congenital disorders of glycosylation.

Authors:  Sandra Supraha Goreta; Sanja Dabelic; Jerka Dumic
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.